Sunday |
4:00 pm - 8:00 pm | Arrival and Check-in |
6:00 pm | Dinner |
7:30 pm - 7:40 pm | Welcome / Introductory Comments by GRC Site Staff |
7:40 pm - 9:30 pm | Keynote Session: TB Treatment - The Way Ahead |
| Discussion Leader: David Barros (GlaxoSmithKline R&D, Spain) |
7:40 pm - 7:50 pm | Opening Remarks |
7:50 pm - 8:00 pm | Introduction by Discussion Leader |
8:00 pm - 8:50 pm | Carl Nathan (Weill Cornell Medical College, USA) "TB Treatment Shortening: Dream or Reality?" |
8:50 pm - 9:10 pm | Discussion |
9:10 pm - 9:30 pm | General Discussion |
Monday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Physiology, Metabolism and Pathogenesis |
| Discussion Leader: Sabine Ehrt (Weill Cornell Medical College, USA) |
9:00 am - 9:25 am | Michael Niederweis (University of Alabama, Birmingham, USA) "The Necrosis-Inducing Toxin of
Mycobacterium tuberculosis
" |
9:25 am - 9:35 am | Discussion |
9:35 am - 10:00 am | Olivier Neyrolles (University of Toulouse, France) "Nitrogen Metabolism in M. tuberculosis: From Basics to Potential
Drug Targets" |
10:00 am - 10:10 am | Discussion |
10:10 am - 10:45 am | Coffee Break |
10:45 am - 11:10 am | Bree Aldridge (Tufts University, USA) "Characterizing Mycobacterial
Drug Tolerance by
Live-Cell Microscopy" |
11:10 am - 11:20 am | Discussion |
11:20 am - 11:45 am | Eric Rubin (Harvard School of Public Health, USA) "Daring to Be Different -
Heterogeneity Among Identical Twins" |
11:45 am - 11:55 am | Discussion |
11:55 am - 12:20 pm | Kelly Flentie (Washington University in St. Louis School of Medicine, USA) "Chemical Dissection of the Contribution of Lipid Composition Changes to Mycobacterium tuberculosis Persister Formation" |
12:20 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:30 pm | Free Time |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm - 8:00 pm | Lessons Learned from Other Microbes |
| Discussion Leader: Clifton Barry (National Institute of Allergy and Infectious Diseases, NIH, USA) |
6:00 pm - 6:30 pm | Katherine Young (Merck & Co., Inc., USA) "Screening Strategies for Antibacterial Hit Discovery: Can They Be Leveraged for TB?" |
6:30 pm - 6:40 pm | Discussion |
6:40 pm - 7:10 pm | David Pompliano (Revolution Medicines, USA) "Pharmaceutical Analogues
of Natural Products from Iterative Synthetic Coupling of Simple Building Blocks" |
7:10 pm - 7:20 pm | Discussion |
7:20 pm - 7:50 pm | Paolo Denti (University of Cape Town, South Africa) "PK/PD Modelling and Simulation in TB/HIV" |
7:50 pm - 8:00 pm | Discussion |
8:00 pm | Dinner |
Tuesday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | New Targets, Target Identification Approaches and Mechanism of Action Studies |
| Discussion Leader: David Sherman (Seattle Biomedical Research Institute, USA) |
9:00 am - 9:25 am | Valerie Mizrahi (University of Cape Town, South Africa) "Identification
of Vulnerable Targets in Core Metabolic Pathways of M. tuberculosis " |
9:25 am - 9:35 am | Discussion |
9:35 am - 10:00 am | Babak Javid (Tsinghua University School of Medicine, China) "The Indirect Path to Targeting
Rifampicin Phenotypic Resistance" |
10:00 am - 10:10 am | Discussion |
10:10 am - 11:15 am | Group Photo / Coffee Break |
11:15 am - 11:40 am | Jean-Emmanuel Hugonnet (Cordeliers Research Center, France) "Beta-Lactam Targets in Mycobacterium tuberculosis" |
11:40 am - 11:50 am | Discussion |
11:50 am - 12:15 pm | Thomas Meier (Max-Planck Institute of Biophysics, Germany) "Structure of the ATP
Synthase Fo Rotor from Mycobacteria and Inhibition Mechanism by the Anti-TB
Drug Bedaquiline" |
12:15 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:30 pm | Free Time |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm - 8:00 pm | Targeting Mycobacterium tuberculosis in the Host |
| Discussion Leader: Eric Rubin (Harvard School of Public Health, USA) |
6:00 pm - 6:30 pm | Philana Lin (Children's Hospital of Pittsburgh, USA) "Strategies of Mtb:
Strength in Diversity" |
6:30 pm - 6:40 pm | Discussion |
6:40 pm - 7:10 pm | Veronique Dartois (New Jersey Medical School, USA) "How to Predict Drug Distribution into Tubercular Lesions?" |
7:10 pm - 7:20 pm | Discussion |
7:20 pm - 7:50 pm | Anne Lenaerts (Colorado State University, USA) "Implementation of the
C3HeB/FeJ Mouse Model in TB Drug Development" |
7:50 pm - 8:00 pm | Discussion |
8:00 pm | Dinner |
Wednesday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | "Omics" in TB Drug Discovery |
| Discussion Leader: Tanya Parish (Infectious Disease Research Institute, USA) |
9:00 am - 9:25 am | Teresa Cortes (London School of Hygiene and Tropical Medicine, United Kingdom) "Understanding the Fundamental
Biology of Mycobacterium tuberculosis by Integrated 'omic' Analysis" |
9:25 am - 9:35 am | Discussion |
9:35 am - 10:00 am | D. Branch Moody (Harvard Medical School, USA) "Organism-Wide Metabolomic Profiling of M. tuberculosis Detects Pathogen Responses to Drug Treatment" |
10:00 am - 10:10 am | Discussion |
10:10 am - 10:40 am | Coffee Break |
10:40 am - 11:05 am | Kyu Rhee (Weill Cornell Medical College, USA) "The Intrabacterial Pharmacology of Antimycobacterial Compounds" |
11:05 am - 11:15 am | Discussion |
11:15 am - 11:40 am | Robert Moritz (Institute for Systems Biology, USA) "Democratization of Proteomics Tools for TB Biomarker and Drug Discovery Efforts" |
11:40 am - 11:50 am | Discussion |
11:50 am - 12:15 pm | Wendy Marriner (National Institute of Allergy and Infectious Diseases, NIH, USA) "Efforts Towards Trehalose-Derived MTb-Specific PET Probes" |
12:15 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:30 pm | Free Time |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm - 8:00 pm | New Strategies in TB Drug Discovery |
| Discussion Leader: David Olsen (Merck & Co, Inc., USA) |
6:00 pm - 6:25 pm | Richard Lee (St. Jude Children's Research Hosipital, USA) "Efflux Busting to Make
Better TB Drugs" |
6:25 pm - 6:30 pm | Discussion |
6:30 pm - 6:55 pm | Alfonso Mendoza (GlaxoSmithKline, Spain) "Antitubercular Drug Discovery
with DNA-Encoded Chemical Libraries" |
6:55 pm - 7:00 pm | Discussion |
7:00 pm - 7:25 pm | David Russell (Cornell University, USA) "Exploitation of the Host Environment in Anti-TB Drug Discovery" |
7:25 pm - 7:30 pm | Discussion |
7:30 pm - 7:55 pm | Chris Walpole (Structural Genomics Consortium, University of Toronto, Canada) "SDDC: Taking a Different
Road to Structure-Based Drug Discovery for TB" |
7:55 pm - 8:00 pm | Discussion |
8:00 pm | Dinner |
Thursday |
7:30 am - 8:30 am | Breakfast |
8:30 am - 9:00 am | Business Meeting |
| Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair |
9:00 am - 12:30 pm | Hit to Lead Development |
| Discussion Leader: Courtney Aldrich (University of Minnesota, USA) |
9:00 am - 9:25 am | Sophie Lagrange (Sanofi TSU ID, France) "On the Way to a New Drug Candidate for Tuberculosis" |
9:25 am - 9:35 am | Discussion |
9:35 am - 10:00 am | Dickon Alley (Anacor Pharmaceuticals, USA) "Leucyl-tRNA Synthetase: The Discovery of a New Class of Oral Protein Synthesis Inhibitors" |
10:00 am - 10:10 am | Discussion |
10:10 am - 10:40 am | Coffee Break |
10:40 am - 11:05 am | Philip Hipskind (Lilly Research Laboratories, USA) "Utilization of a Formal
Hit Assessment Approach to Efficient Anti-Tuberculosis Drug Discovery" |
11:05 am - 11:15 am | Discussion |
11:15 am - 11:40 am | Debrorah Hung (Harvard University, USA) "Chemical and Genetic
Approaches to In Vivo Target Validation" |
11:40 am - 11:50 am | Discussion |
11:50 am - 12:15 pm | Arnab Chatterjee (California Institute for Biomedical Research, USA) "An Opportunistic Approach
to the Discovery of New Drugs for TB Using a Variety of HTS Assays" |
12:15 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:30 pm | Free Time |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm - 8:00 pm | From Leads to Clinical Development |
| Discussion Leader: Debra Hanna (Critical Path Institute, USA) |
6:00 pm - 6:25 pm | Anna Upton (TB Alliance, USA) "Novel Series on the Horizon for Drug Sensitive and Drug Resistant TB" |
6:25 pm - 6:35 pm | Discussion |
6:35 pm - 7:00 pm | Neil Schluger (Columbia University Medical Center, USA) "Challenges to Translating Basic Science to Improved Regimens for Latent
and Active Tuberculosis" |
7:00 pm - 7:10 pm | Discussion |
7:10 pm - 7:35 pm | Jeffrey Hafkin (Otsuka, USA) "Updates from the Delamanid Development Program" |
7:35 pm - 7:45 pm | Discussion |
7:45 pm - 8:00 pm | Closing Remarks |
8:00 pm | Dinner |
Friday |
7:30 am - 8:30 am | Breakfast |
9:00 am | Departure |